Shares Magazine
1.53p+0.09 (+6.27%)21 Nov 2024, 17:17
Jump to:
Hemogenyx Pharmaceuticals PLC Fundamentals
| Company Name | Hemogenyx Pharmaceuticals PLC | Last Updated | 2024-11-21 |
|---|---|---|---|
| Industry | Biotechnology | Sector | Healthcare |
| Shares in Issue | 1.342 bn | Market Cap | £20.46 m |
| PE Ratio | 0.00 | Dividend per Share | 0 |
| Dividend Yield | 0 | Dividend Cover | 0 |
| EPS | -£0.01 | EPS Growth (%) | 0 |
| PEG | 0 | DPS Growth (%) | 0 |
| Debt Ratio | 0.4552 | Debt Equity Ratio | 0.8253 |
| Asset Equity Ratio | 2.0230 | Cash Equity Ratio | 0.5433 |
| Quick Ratio | 4.3785 | Current Ratio | 4.38 |
| Price To Book Value | 6.5660 | ROCE | 0 |
Hemogenyx Pharmaceuticals PLC Dividends
| Type | Ex-Date | Pay Date | Currency | Net Dividend | Year Total |
|---|
Hemogenyx Pharmaceuticals PLC Company Financials
| Assets | 2023 | 2022 | 2021 |
|---|---|---|---|
| Tangible Assets | £3.31 m | £3.92 m | £797,129.00 |
| Intangible Assets | £441,493.00 | £441,493.00 | £441,493.00 |
| Investments | 0 | 0 | 0 |
| Total Fixed Assets | £3.94 m | £4.50 m | £1.38 m |
| Stocks | 0 | 0 | 0 |
| Debtors | £1,074.00 | £146.00 | £1,386.00 |
| Cash & Equivalents | £1.25 m | £2.53 m | £6.84 m |
| Other Assets | 0 | 0 | 0 |
| Total Assets | £6.11 m | £7.09 m | £8.52 m |
| Liabilities | 2023 | 2022 | 2021 |
|---|---|---|---|
| Creditors within 1 year | £652,085.00 | £748,411.00 | £352,841.00 |
| Creditors after 1 year | £2.67 m | £3.10 m | 0 |
| Other Liabilities | 0 | 0 | 0 |
| Total Liabilities | £3.32 m | £3.85 m | £352,841.00 |
| Net assets | £2.78 m | £3.24 m | £8.17 m |
| Equity | 2023 | 2022 | 2021 |
|---|---|---|---|
| Called up share capital | £11.76 m | £9.80 m | £9.80 m |
| Share Premium | £19.94 m | £16.81 m | £16.81 m |
| Profit / Loss | -£6.70 m | -£3.99 m | -£5.11 m |
| Other Equity | £2.82 m | £3.28 m | £8.19 m |
| Preference & Minorities | -£37,723.00 | -£31,908.00 | -£24,240.00 |
| Total Capital Employed | £2.78 m | £3.24 m | £8.17 m |
| Ratios | 2023 | 2022 | 2021 |
|---|---|---|---|
| Debt Ratio | £0.49 | £0.49 | 0 |
| Debt-to-Equity | £0.95 | £0.95 | 0 |
| Assets / Equity | 2.0230 | 2.0230 | 2.0230 |
| Cash / Equity | 0.5433 | 0.5433 | 0.5433 |
| EPS | -£0.01 | -£0.01 | -£0.01 |
| Cash Flow | 2023 | 2022 | 2021 |
|---|---|---|---|
| Cash from operating activities | -£6.11 m | -£2.91 m | -£2.63 m |
| Cashflow before financing | -£1.66 m | -£3.02 m | £6.15 m |
| Increase in Cash | -£1.69 m | -£3.43 m | £5.21 m |
| Income | 2023 | 2022 | 2021 |
|---|---|---|---|
| Turnover | 0 | 0 | 0 |
| Cost of sales | £1.68 m | £2.20 m | £283,647.00 |
| Gross Profit | -£1.68 m | -£2.20 m | -£283,647.00 |
| Operating Profit | -£6.47 m | -£4.00 m | -£2.70 m |
| Pre-Tax profit | -£6.70 m | -£3.99 m | -£5.11 m |
Hemogenyx Pharmaceuticals PLC Company Background
| Sector | Healthcare |
|---|---|
| Activities | Hemogenyx Pharmaceuticals PLC is an operator of a biotechnology company intended to focus on the discovery, development, and commercialization of novel therapies and treatments for blood diseases, like leukaemia and lymphoma. The company'stechnologies aim to change the way in which bone marrow/hematopoietic stem cell transplants are performed and improve their efficacy, its three distinct products include an immunotherapy product for the treatment of relapsed/refractory acute myeloid leukaemia (AML) and patient conditioning, the bi-specific antibody, for the treatment of AML and a community-based rehabilitation/Biomedical engineering platform, enabling users to generate treatments for existing and emerging viral infections. |
| Latest Interim Date | 27 Sep 2024 |
| Latest Fiscal Year End Date | 25 Apr 2024 |
Hemogenyx Pharmaceuticals PLC Directors
| Appointed | Name | Position |
|---|---|---|
| 2024-04-25 | Mr. Peter Redmond | Non-Executive Director |
| 2017-10-05 | Mr. Geoffrey Gilbert Dart | Executive Director,Chairman |
| 2018-11-05 | Mr. Lawrence Pemble | Executive Director,Chief Operating Officer |
| 2018-04-03 | Mr. Adrian Richard Thorpe Beeston | Non-Executive Director |
| 2024-04-25 | Dr. Vladislav Sandler | Executive Director,Chief Executive Officer |
| 2024-04-25 | Ms. Alexis M. Sandler | Non-Executive Director |
| 2019-01-04 | Dr. Robin Campbell | Non-Executive Director |
| 2024-04-25 | Professor Sir. Marc Feldmann | Non-Executive Director,Chairman |
Hemogenyx Pharmaceuticals PLC Contact Details
| Company Name | Hemogenyx Pharmaceuticals PLC |
|---|---|
| Address | 5 Fleet Place, London, EC4M 7RD |
| Telephone | |
| Website | https://www.hemogenyx.com |
Hemogenyx Pharmaceuticals PLC Advisors
| Financial Adviser | Peterhouse Corporate Finance Ltd |
|---|---|
| Phone | +44 2074690930 |
| Fax | +44 2072209798 |
| Stockbroker | Optiva Securities Ltd |
|---|---|
| Phone | +44 2031371902 |
| Solicitor | Charles Russell Speechlys LLP |
|---|---|
| Phone | +44 2072035000 |
| Bank | Metro Bank Plc |
|---|
| Auditor | PKF Littlejohn |
|---|---|
| Phone | +44 2075162200 |
| Fax | +44 2075162400 |
| Registrar | Computershare Investor Services PLC |
|---|---|
| Phone | +44 3707020003 |
| Fax | +44 3707036101 |
| Financial PR Adviser | Camarco |
|---|---|
| Phone | +44 02037574980 |
Most Read
Receive our
daily news email
Subscribe to the latest investing news by entering your email address below
You can opt out at any time.
For five days a week you will get
- The latest company news
- Insight into investment trends
- Round-up of director's buys and sells
- Articles from Shares magazine
